Compare AKR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | TVTX |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 1993 | N/A |
| Metric | AKR | TVTX |
|---|---|---|
| Price | $20.15 | $34.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $22.00 | ★ $37.21 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 18.54 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | $389,489,000.00 | ★ $435,826,000.00 |
| Revenue This Year | N/A | $120.36 |
| Revenue Next Year | $16.18 | $37.33 |
| P/E Ratio | $160.61 | ★ N/A |
| Revenue Growth | 6.01 | ★ 114.22 |
| 52 Week Low | $16.98 | $12.91 |
| 52 Week High | $25.83 | $37.50 |
| Indicator | AKR | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 54.24 |
| Support Level | $19.79 | $33.84 |
| Resistance Level | $20.46 | $35.97 |
| Average True Range (ATR) | 0.43 | 1.45 |
| MACD | -0.01 | -0.33 |
| Stochastic Oscillator | 48.48 | 31.23 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.